Redo-Transcatheter Aortic Valve Implantation Versus Surgical Explantation in Patients With Previous Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.
Nikolaos Ktenopoulos, Anastasios Apostolos, Dimitrios Terentes-Printzios et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis compared redo-transcatheter aortic valve implantation (redo-TAVI) with surgical explantation in patients with prior transcatheter aortic valve implantation. Analyzing data from 6166 patients, the study found that redo-TAVI significantly reduced in-hospital mortality (OR 0.20), 30-day mortality (OR 0.28), and 1-year mortality (OR 0.70) compared to surgical explantation.
Key findings
- Redo-TAVI was associated with lower in-hospital mortality (OR 0.20) compared to TAVI-explantation.
- 30-day mortality was significantly lower in the redo-TAVI group (OR 0.28).
- Patients undergoing redo-TAVI experienced shorter hospitalization by an average of 6.29 days.
- Redo-TAVI had a higher risk of greater-than-mild paravalvular leak (OR 80.12).
Why it matters
The findings suggest that redo-TAVI may be a safer and more effective option for patients with failed transcatheter heart valves, potentially leading to better short-term outcomes and reduced healthcare costs due to shorter hospital stays.